PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced
Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR
Mutations (A Pediatric MATCH Treatment Trial)
Does the drug LY3023414 help patients with cancers that have spread to other places
in the body and do not respond to treatment?
Basic Study Information
Purpose:Location: University of Rochester
This phase II Pediatric MATCH trial studies how well PI3K/mTOR inhibitor LY3023414
treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders
or PI3K/MTOR mutations that have spread to other places in the body and have come
back or do
not respond to treatment. PI3K/mTOR inhibitor LY3023414 may stop the growth of cancer
by blocking some of the enzymes needed for cell growth.
Study Contact InformationPhone: (585) 275-5830
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search